The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Current status and prospects of HIV treatment
Open accessAbstract
Current antiviral treatments can reduce HIV-associated morbidity, prolong survival, and prevent HIV transmission. Combination antiretroviral therapy (cART) containing preferably three active drugs from two or more classes is required for durable virologic suppression. Regimen selection is based on virologic efficacy, potential for adverse effects, pill burden and dosing frequency, drug-drug interaction potential, resistance test results, comorbid conditions, social status, and cost. With prolonged virologic suppression, improved clinical outcomes, and longer survival, patients will be exposed to antiretroviral agents for decades. Therefore, maximizing the safety and tolerability of cART is a high priority. Emergence of resistance and/or lack of tolerability in individual patients require availability of a range of treatment options. Development of new drugs is focused on improving safety (e.g. tenofovir alafenamide) and/or resistance profile (e.g. doravirine) within the existing drug classes, combination therapies with improved adherence (e.g. single-tablet regimens), novel mechanisms of action (e.g. attachment inhibitors, maturation inhibitors, broadly neutralizing antibodies), and treatment simplification with infrequent dosing (e.g. long-acting injectables). In parallel with cART innovations, research and development efforts focused on agents that target persistent HIV reservoirs may lead to prolonged drug-free remission and HIV cure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palella, F. J., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., Aschman, D. J., & Holmberg, S. D. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381301 · Cited by 9,405
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Guaraldi, G., Orlando, G., Zona, S., Menozzi, M., Carli, F., Garlassi, E., Berti, A., Rossi, E., Roverato, A., & Palella, F. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/cir627 · Cited by 1,331
Changing patterns of mortality across Europe in patients infected with HIV-1
Mocroft, A., Vella, S., Benfield, T., Chiesi, A., Miller, V, Gargalianos, P., Monforte, A. D., Yust, I., Bruun, J., Phillips, A., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03201-2 · Cited by 1,270
Estimated HIV Incidence in the United States, 2006–2009
Prejean, J., Song, R., Hernandez, A., Ziebell, R., Green, T., Walker, F., Lin, L. S., An, Q., Mermin, J., Lansky, A., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017502 · Cited by 1,071
Attia, S., Egger, M., Müller, M., Zwahlen, M., & Low, N. (2009) · AIDS · doi:10.1097/qad.0b013e32832b7dca · Cited by 1,001
Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection
Walmsley, S. L., Antela, A., Clumeck, N., Duiculescu, D., Eberhard, A., Gutiérrez, F., Hocqueloux, L., Maggiolo, F., Sandkovsky, U., Granier, C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215541 · Cited by 876
Montaner, J. S., Lima, V. D., Barrios, R., Yip, B., Wood, E., Kerr, T., Shannon, K., Harrigan, P. R., Hogg, R. S., Daly, P., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60936-1 · Cited by 780
Cited by
Drug combinations: a strategy to extend the life of antibiotics in the 21st century
Tyers, M., & Wright, G. D. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0141-x · Cited by 820
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Riva, L., Yuan, S., Yin, X., Martin-Sancho, L., Matsunaga, N., Pache, L., Burgstaller-Muehlbacher, S., De Jesus, P. D., Teriete, P., Hull, M. V., et al. (2020) · Nature · doi:10.1038/s41586-020-2577-1 · Cited by 760
QSAR-Based Virtual Screening: Advances and Applications in Drug Discovery
Neves, B. J., Braga, R. C., Melo-Filho, C. C., Moreira-Filho, J. T., Muratov, E. N., & Andrade, C. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01275 · Cited by 494
Dopamine, Immunity, and Disease
Channer, B., Matt, S. M., Nickoloff-Bybel, E. A., Pappa, V., Agarwal, Y., Wickman, J., & Gaskill, P. J. (2023) · Pharmacological Reviews · doi:10.1124/pharmrev.122.000618 · Cited by 308
Drug Combinations Against Soil-Transmitted Helminth Infections
(2019) · Advances in Parasitology · doi:10.1016/bs.apar.2018.08.002 · Cited by 92
Metadata
- Authors
- Cihlar, T., & Fordyce, M.
- Venue
- Current Opinion in Virology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 18
- Pages
- 50-56
- ISSN
- 1879-6257 (ISSN-L)
- OpenAlex
- W2315025523
- Cited by
- 337
- References
- 42
- FWCI
- 7.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current status and prospects of HIV treatment. https://app.cochat.ai/papers/10.1016/j.coviro.2016.03.004
- The paper
- Cihlar, T., & Fordyce, M. (2016). Current status and prospects of HIV treatment. Current Opinion in Virology. https://doi.org/10.1016/j.coviro.2016.03.004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.